RxDoctor Payments Data

Darwin Brown, MD

Endocrinology, Diabetes & Metabolism · Decatur, GANPI 1992751259

Payments from drug & device makers

$927in general payments, 2019–2025

Across 48 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$139
  • Lilly USA, LLC$121
  • Xeris Pharmaceuticals, Inc.$112
  • Novo Nordisk$78
  • Dexcom, Inc.$70
  • Boehringer Ingelheim$51
  • plus $356 from 13 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$927 in reported general payments places this provider in the 25th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$139,921
Medicare patients
431
Services billed
2,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide264$434,029
JardianceEmpagliflozin109$142,295
MounjaroTirzepatide84$128,756
TrulicityDulaglutide49$92,567
Tresiba Flextouch U-100Insulin Degludec57$53,888
Novolog FlexpenInsulin Aspart138$43,712
RybelsusSemaglutide22$43,068
Humulin R U-500 KwikpenInsulin Regular, Human14$41,223
FarxigaDapagliflozin Propanediol36$30,085
Lantus SolostarInsulin Glargine,hum.Rec.Anlog160$28,661
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$28,267
Nano 2nd Gen Pen NeedlePen Needle, Diabetic189$27,526
Teriparatide12$26,946
Tresiba Flextouch U-200Insulin Degludec24$26,000
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$24,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$78$488,538313 claims
Lilly USA, LLCMounjaro, Trulicity$121$221,322133 claims
Boehringer IngelheimJardiance, Tradjenta$51$163,880127 claims
AstraZenecaFarxiga$20$30,08536 claims
AbbVieSynthroid$31$9,96188 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$6,367664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →